

Best Poster Award – Third Prize

The Perilousness of Antidepressant Drugs in a Real-world Cohort of Patients with Acute Coronary Syndrome

A Denegri,¹ L Raeber,² S Windecker,² B Gencer,³ F Mach,³ N Rodondi,²
D Heg,² D Nanchen,⁴ C Matter⁵ and TF Luescher⁵

1. Mantova, Italy; 2. Berne, Switzerland; 3. Geneva, Switzerland; 4. Lausanne, Switzerland; 5. Zurich, Switzerland

Citation: *European Cardiology Review* 2020;15:e26. **DOI:** <https://doi.org/10.15420/ecr.2020.15.1.PO3>


Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Background: Although antidepressant therapy has been related to increased cardiovascular risk, depression, and its adverse effects on prognosis, is a well-recognised entity among acute coronary syndrome (ACS) patients. The aim of the study was to evaluate prevalence and outcome of antidepressant treatment in a real-world cohort of ACS patients.

Methods: We sought to assess the prevalence of established antidepressant therapy (ADT) and its impact among 2,168 all-comers patients admitted to four Swiss university hospitals for ACS and enrolled in the prospective multicentre SPUM registry (NCT01000701). The primary endpoint was all-cause mortality. The association between ADT and mortality was tested by adjusted multivariable conditional logistic regression.

Results: Out of 2,168 ACS patients, 141 patients (6.5%) were on ADT. Compared with the general ACS population, ADT patients were more likely to be unemployed ($p=0.001$), men ($p=0.002$), diabetic ($p=0.010$) and already treated with cardiovascular (CV) preventive therapy with statins or beta-blockers ($p<0.001$). Patients with ADT had a twofold risk of all-cause mortality (OR 2.2, 95% CI [1.20–4.00], $p=0.009$) with a threefold risk of non-CV death (OR 3.24, 95% CI [1.10–9.70], $p=0.026$) and a 77% not significant higher risk of CV death (OR 1.77, 95% CI [0.83–3.80], $p=0.130$). This enhanced risk persisted after adjustment for confounding significant baseline characteristics, with a 47% (adjusted HR 1.47, 95% CI [1.05–1.70], $p=0.032$, Figure 1).

Figure 1.



Conclusion: Among a real-world cohort of ACS patients, ADT is associated with a significantly increased rate of all-cause mortality and non-CV death. These observations should lead clinicians to further individualise ADT, employing newer and safer ADT, generally associated with a lower CV risk. ■